""The receptors targeted by semaglutide are found in the brain but also in the gut, pancreas and other tissues. That's why Ozempic has widespread effects including slowing the movement of food through the digestive tract and lowering blood sugar levels. In contrast, BRP appears to act specifically in the hypothalamus, which controls appetite and metabolism.""
""The discovery relied heavily on artificial intelligence to sort through a large group of molecules known as prohormones. These molecules are initially inactive but can be cut into smaller fragments called peptides, some of which function as hormones that influence processes like metabolism in the brain and body.""
Researchers at Stanford Medicine have identified a molecule named BRP that mimics the appetite-suppressing effects of Ozempic, reducing appetite and body weight in animal studies. Unlike Ozempic, BRP avoids common side effects such as nausea and muscle loss. It operates through a distinct biological pathway, specifically targeting neurons in the hypothalamus, which regulates appetite and metabolism. The discovery utilized artificial intelligence to analyze prohormones, leading to the identification of this promising peptide for potential human clinical trials.
Read at ScienceDaily
Unable to calculate read time
Collection
[
|
...
]